L. Battipaglia

CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration—In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window

A. Sala, S. Catinella, Valentina Bagnacani, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.

S. Catinella, L. Venturi, P. Puccini, 2022, Journal of medicinal chemistry.

Bronchodilator Activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a Potent, Long-Acting, and Selective Muscarinic M3 Receptor Antagonist

M. Zaniboni, G. Rossoni, G. Villetti, 2010, Journal of Pharmacology and Experimental Therapeutics.

CHF 5407 ) a Potent , Long-Acting and Selective Muscarinic M 3 Receptor Antagonist

G. Villetti, M. Civelli, F. Pastore, 2010 .

Microsoft Word - 1192223-file00

M. Zaniboni, M. Civelli, F. Pastore, 2010 .

Synthesis and anticonvulsant activity of a class of 2-amino 3-hydroxypropanamide and 2-aminoacetamide derivatives.

M. Mazzuferi, G. Villetti, A. Rizzi, 2006, Bioorganic & Medicinal Chemistry.

Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.

S. Catinella, Valentina Bagnacani, F. Amadei, 2017, Journal of medicinal chemistry.